Sema4 Appoints Corporate Development Executive Kareem Saad as Chief Strategy Officer
Stamford, CT — December 18, 2017 — Sema4, a health information company providing advanced genomic testing, today announced the appointment of Kareem Saad as Chief Strategy Officer. Mr. Saad has extensive experience in the healthcare and life sciences sector, where, over the span of a twenty-year career, he has been responsible for developing and implementing strategic execution plans, managing partner businesses, and completing corporate, fundraising and business development transactions worth more than $500 million. At Sema4, he will lead a major push for corporate strategy and growth, working closely with business partners and current as well as prospective investors.
“Kareem has tremendous expertise in scaling healthcare and science businesses, from startups to very large organizations,” said Eric Schadt, PhD, Chief Executive Officer of Sema4. “As we expand our offerings and rapidly grow our existing business, we are very fortunate to have Kareem on the Sema4 team to help realize the strategic vision for our company and significantly accelerate progress along our corporate roadmap.”
Mr. Saad was previously Chief Commercial Officer and Executive Vice President of Strategy and Business Development for Source Medical Solutions, the leading provider of practice management and EMR solutions for the ambulatory surgical space. Before that, he was a director in Dell’s Healthcare and Life Sciences division, responsible for managing Dell’s healthcare partner program where he grew that business to over $180M. Prior to that, he served in a number of executive leadership roles at midsize and early stage biotech and healthcare IT companies and began his career by co-founding InphoGene Bioinformatics, a pioneering biobanking company with strategic financial backing from a number of marquee investors, including IBM. Mr. Saad earned his MBA at the University of Chicago Booth School of Business and his bachelor’s degree in biochemistry and molecular biology at the University of British Columbia.>
“It is a rare opportunity to join a startup with the kinds of resources Sema4 has at its disposal: a strategic affiliation with Mt. Sinai, nearly 400 highly skilled employees, robust revenue, and significant resources already in place, and that is poised to significantly disrupt the personalized healthcare market” said Mr. Saad. “This company is poised for dramatic growth, and I look forward to achieving that potential as we provide consumers, researchers, and clinicians with the tools, information, and knowledge to improve health outcomes.”About Sema4
Sema4 is a health information company founded on the idea that more data, deeper analysis, and increased engagement will improve the diagnosis, treatment, and prevention of disease. A Mount Sinai Health System venture based in Stamford, Conn., Sema4 is enabling physicians and consumers to more seamlessly engage the digital universe of health data, from genome test results and clinical records to wearable sensor metrics and more. The company currently offers advanced genome-based diagnostics for reproductive health and is building predictive models of complex disease. Sema4 believes that patients should be treated as partners, and that data should be shared for the benefit of all.